Navigation Links
Poniard Pharmaceuticals Appoints Four New Members to Clinical Advisory Board
Date:5/28/2008

rcialization of innovative oncology products to impact the lives of people with cancer. Picoplatin, the Company's lead platform product candidate, is a new generation platinum therapy with an improved safety profile relative to existing platinum-based cancer therapies. Picoplatin is designed to overcome platinum resistance associated with chemotherapy in solid tumors, and is being studied in multiple cancer indications, combinations and formulations. Clinical trials of intravenous picoplatin include a Phase 3 trial in small cell lung cancer and Phase 2 trials in metastatic colorectal and hormone-refractory prostate cancers, as well as a clinical trial of oral picoplatin in solid tumors. Picoplatin has not been approved by any regulatory authority for use in humans. For additional information please visit http://www.poniard.com.

This release contains forward-looking statements, including statements regarding the Company's business objectives and strategic goals, drug development plans, results of clinical trials and the potential safety and efficacy of its products in development. The Company's actual results may differ materially from those indicated in these forward-looking statements based on a number of factors, including risks and uncertainties associated with the Company's research and development activities; the results of pre-clinical and clinical testing; the receipt and timing of required regulatory approvals; the market's acceptance of the Company's proposed products; the Company's anticipated operating losses, need for future capital and ability to obtain future funding; competition from third parties; the Company's ability to preserve and protect intellectual property rights; the Company's dependence on third-party manufacturers and suppliers; the Company's lack of sales and marketing experience; the Company's ability to attract and retain key personnel; changes in technology, government regulatio
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Poniard Pharmaceuticals Reports First Quarter 2008 Financial Results and Corporate Update
2. Poniard Pharmaceuticals Announces Upcoming Conference Participation
3. Poniard Pharmaceuticals Appoints Robert De Jager, M.D., as Chief Medical Officer
4. Poniard Pharmaceuticals Announces European Commission Grants Orphan Medicinal Product Designation to Picoplatin for Treatment of Small Cell Lung Cancer
5. Poniard Pharmaceuticals Announces Upgrade of Stock Listing to NASDAQ Global Market
6. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
7. XTL Biopharmaceuticals Announces Appointment of Laurence N. Charney to Board of Directors
8. Sonus Pharmaceuticals and OncoGenex Technologies to Merge
9. American Stock Exchange Lists the Common Stock of Rexahn Pharmaceuticals, Inc.
10. AMAG Pharmaceuticals, Inc. and 3SBio, Inc. Announce Strategic Partnership to Develop and Commercialize Ferumoxytol in China
11. Amylin Pharmaceuticals to Present at Annual Meeting of Stockholders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... 2014 A new report by ... applications and geography) - Size, Share, Global Trends, Company ... Forecast, 2013 - 2020", suggests that the global surgical ... 2020 registering a CAGR of 11.1% from 2014 to ... the electro surgical devices in operative procedures by providing ...
(Date:7/29/2014)... 2014 Philadelphia’s newest entrepreneurial incubation space is ... start. The Innovation Center @3401 , a collaborative effort ... Science Center to help attract and nurture start-up businesses ... 28. , The Innovation Center @3401 (ic@3401), ... Streets, is the new home of DreamIt Ventures ...
(Date:7/29/2014)... July 29, 2014  United Therapeutics Corporation (NASDAQ: ... financial results for the second quarter ended ... shows that our medicines are reaching increasing ... hypertension (PAH)," said Martine Rothblatt, Ph.D., United ... commercial launch this quarter of our extended-release ...
(Date:7/29/2014)... Dr. Jason Wendel – recipient of a Regional ... the Top 10 Plastic Surgeon Specialists for Nashville, TN – ... complete line includes a Hydration Booster, Retexturing Night Crème, and ... skin a younger, more radiant appearance while protecting them from ... that is why at Dr. J. J. Wendel Plastic Surgery, ...
Breaking Biology Technology:Global Surgical Equipment Market is expected to reach $12.1 billion by 2020 - Allied Market Research 2Global Surgical Equipment Market is expected to reach $12.1 billion by 2020 - Allied Market Research 3Innovation Center @3401 Opens for Business; DreamIt Ventures and Point.io First Residents 2Innovation Center @3401 Opens for Business; DreamIt Ventures and Point.io First Residents 3United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 2United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 3United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 4United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 5United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 6United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 7United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 8United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 9United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 10United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 11United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 12United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 13Dr. J. J. Wendel Launches New Line of Skin Care Products 2
... Cornerstone Therapeutics Inc. (Nasdaq CM: CRTX), a specialty ... products primarily for the respiratory and related markets, today ... 8:30 AM ET on Wednesday, November 4, 2009, to ... 30, 2009. Management will also provide an update ...
... ... , ... (PRWEB) October 21, 2009 -- iLife Americas, LLC, a leading developer and marketer of ... its line of iLife wellness and therapeutic products. Officially opened on September 1, 2009, ...
... symbol: SBS , CALGARY, Oct. 21 /PRNewswire-FirstCall/ - ... Advitech Inc. ("Advitech") has entered into a definitive ... outstanding shares of Botaneco Specialty Ingredients Inc. ("Botaneco") ... ("Avrio"). SemBioSys will hold an initial 9.48 percent ...
Cached Biology Technology:Cornerstone Therapeutics to Host Third Quarter 2009 Conference Call 2Cornerstone Therapeutics to Host Third Quarter 2009 Conference Call 3iLife Americas, LLC Enters U.S. Wellness and Therapeutic Markets 2SemBioSys provides an update on Botaneco 2SemBioSys provides an update on Botaneco 3SemBioSys provides an update on Botaneco 4
(Date:7/28/2014)... Amundsen reached the South Pole in 1911, but new ... any human. , Using data from 16 ice cores ... including the South Pole, a group led by Joe ... Nevada, created the most accurate and precise reconstruction to ... new record, described in an article published today in ...
(Date:7/28/2014)... in the United States have a circulatory problem of ... painful and may even require surgery in serious cases. ... and, in turn, limb amputation. , At The University ... School, scientists tested a non-surgical preventative treatment in a ... with increased blood circulation. Their proof-of-concept study appears ...
(Date:7/28/2014)... John Essigmann and colleagues from the University of Washington had ... they could induce the virus to mutate uncontrollably, they could ... strategy that our immune system uses against many viruses. ... to mutate at an enhanced rate, as expected. But it ... clinical trial reported in 2011. In a new study, however, ...
Breaking Biology News(10 mins):Lead pollution beat explorers to South Pole, persists today 2Lead pollution beat explorers to South Pole, persists today 3Scientists discover genetic switch that can prevent peripheral vascular disease in mice 2Forced mutations doom HIV 2Forced mutations doom HIV 3Forced mutations doom HIV 4
... from the University of York suggests protected areas in ... iconic Acacia tree., Acacia, the thorny flat-topped tree that ... ecosystem diversity. However, the researchers found that the majority ... protected area network, which includes national parks, nature and ...
... is available in German . , ... University,s Center for Biotechnology (CeBiTec) have paid off: the ... Machine competition, (iGEM) at the Massachusetts Institute of Technology ... their project was to develop a biological filter that ...
... studying freely behaving rats have found that their neurons often ... to be published in EPJ B . These findings ... Bahia Federal University in Salvador, and his colleagues from other ... neuronal networks, memory could be explored in the future. ...
Cached Biology News:Protected areas in East Africa may not be conserving iconic plants 2Protected areas in East Africa may not be conserving iconic plants 3Synthetic biofilter wins through to the top 'Sweet 16' in Boston 2
No description available in Ensembl. Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
5(S)-HETE-d8 is used as an internal standard for the quantification of 5(S)-HETE by stable isotope dilution mass spectrometry....
Full-length cDNA clone CS0DJ013YG01 of T cells (Jurkat cell line) of Homo sapiens (human). [Source:Uniprot/SPTREMBL;Acc:Q86SZ3] Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
...
Biology Products: